Leuprorelin - DURECT/Curaxis
Alternative Names: DURIN™ leuprolide implant; DURIN™-leuprolide; Leuprorelin - Curaxis/DURECT; Leuprorelin - DURECT/Voyager; Leuprorelin - Voyager/DURECT; Memryte implant; VP4896Latest Information Update: 18 Nov 2021
At a glance
- Originator DURECT Corporation; Voyager Pharmaceutical
- Developer Curaxis Pharmaceutical Corporation
- Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Alzheimer's disease
Most Recent Events
- 23 Sep 2010 Curaxis enters into an equity line agreement with Southridge Partners
- 19 Aug 2010 Voyager Pharmaceutical completes reverse merger and becomes publicly traded company called Curaxis Pharmaceutical Corporation; funding secured to resume clinical development of leuprolin
- 07 Nov 2006 A pivotal phase III trial of Memryte™ implant for the treatment of Alzheimer's disease ends early to enable analysis of efficacy data